A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia
about
Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsMolecular therapy for acute myeloid leukaemia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.RUNX1-Evi-1 fusion gene inhibited differentiation and apoptosis in myelopoiesis: an in vivo study.Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic LeukemiaMultiple myeloma in the marrow: pathogenesis and treatments.Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells.Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies.Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model.Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment.The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
P2860
Q26779960-7AA067A3-FCE0-4B81-B56C-50DE60797C63Q26851417-A99FCEA6-A7F3-4DF8-8693-919E3691F632Q33925672-877835FC-3DC2-4057-8990-21FA63D83DA6Q35546759-3ABE0656-8FD8-4FC8-B98E-D345425508A7Q36379789-B79F44C8-FA67-446D-9ABC-BA44B7CBDAF6Q36571783-180B1C35-191A-4347-8A66-44C12A499448Q36725401-25F43DE7-3677-4016-9DED-F3272CC85D21Q38688878-EA3DB432-1C45-4841-B421-6EEF95B85A59Q41084893-0B9333FB-8F81-44E0-BEA7-2FCD1B3CE56AQ47564349-54B09F65-06BF-41BB-B0F3-7F71F10254E7Q51818965-0F23D307-7D83-4B2E-8549-A6D1BF7484FCQ52668197-DF621FAA-9A25-41A5-B1A9-B245F97E43B2Q55396890-208293B9-5B33-4345-A348-888FB534AD3AQ58742654-F5CA74AF-2FDC-4A75-80F0-E337FFBBDA59
P2860
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@ast
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@en
type
label
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@ast
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@en
prefLabel
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@ast
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@en
P2093
P2860
P50
P1476
A phase I/II study of the Janu ...... ractory acute myeloid leukemia
@en
P2093
Kate Newberry
Naveen Pemmaraju
Sara Dellasala
P2860
P304
P356
10.1016/J.CLML.2014.08.003
P407
P50
P577
2014-09-17T00:00:00Z